Ursa Brown‐Glaberman

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso et al. · JAMA Oncology · 2021 · 349 citations · Full text

Medicine, Oncology, Pharmacology +17

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

Roisín M. Connolly, Fengmin Zhao, Kathy D. Miller et al. · Journal of Clinical Oncology · 2021 · 119 citations · Full text

Medicine, Oncology, Pharmacology +17

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

Eve T. Rodler, Priyanka Sharma, William E. Barlow et al. · The Lancet Oncology · 2023 · 98 citations · Full text

Medicine, Oncology, Pharmacology +13

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso et al. · Journal of Clinical Oncology · 2022 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline <i>BRCA</i>-associated breast cancer (SWOG S1416).

Priyanka Sharma, Eve T. Rodler, William E. Barlow et al. · Journal of Clinical Oncology · 2020 · 49 citations

Medicine, Oncology, Pharmacology +14